| Chronic Obstructive Airway Disease
Perforomist vs Yupelri
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Perforomist vs Yupelri with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsYupelri has a higher rate of injection site reactions vs Perforomist based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Yupelri but not Perforomist, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Perforomist
Yupelri
At A Glance
Nebulization
Twice daily
Long-acting beta2-agonist (LABA)
Inhaled (nebulizer)
Once daily
Long-acting muscarinic antagonist
Indications
- Chronic Obstructive Airway Disease
- Bronchitis, Chronic
- Pulmonary Emphysema
- Chronic Obstructive Airway Disease
Dosing
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema 20 mcg (one unit-dose vial) administered twice daily (morning and evening) by nebulization via standard jet nebulizer connected to an air compressor; total daily dose greater than 40 mcg is not recommended.
Chronic Obstructive Airway Disease 175 mcg (one unit-dose vial) inhaled once daily via standard jet nebulizer with mouthpiece.
Contraindications
- Use without an inhaled corticosteroid in patients with asthma
- Hypersensitivity to revefenacin or any component of this product
Adverse Reactions
Most common (>=2%) Diarrhea, nausea, nasopharyngitis, dry mouth, vomiting, dizziness, insomnia
Serious Angina, hypertension or hypotension, tachycardia, arrhythmias, hypokalemia, hyperglycemia, metabolic acidosis
Postmarketing Anaphylactic reactions, urticaria, angioedema, rash, bronchospasm
Most common (>=2%) Cough, nasopharyngitis, upper respiratory tract infection, headache, back pain
Serious Paradoxical bronchospasm, worsening of narrow-angle glaucoma, worsening of urinary retention, immediate hypersensitivity reactions
Postmarketing Dry mouth
Pharmacology
Long-acting beta2-adrenergic receptor agonist (LABA) that acts locally in the lung as a bronchodilator; stimulates adenyl cyclase to increase cyclic AMP levels, causing relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Revefenacin is a long-acting muscarinic antagonist (anticholinergic) that competitively and reversibly inhibits M3 receptors at airway smooth muscle, leading to bronchodilation predominantly through a site-specific effect following inhalation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Perforomist
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (10/12)
Yupelri
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (6/12) · Qty limit (4/12)
UnitedHealthcare
Perforomist
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (5/8)
Yupelri
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Perforomist
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Yupelri
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Perforomist.
Cost estimate not availableAssistance Fund: Chronic Obstructive Pulmonary Disease (COPD)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PerforomistView full Perforomist profile
YupelriView full Yupelri profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.